MAYNE PHARMA GROUP LIMITED — Director's Dealing 2025

Dec 22, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Shawn Patrick O’Brien
Date of last notice	06 December 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan (the ‘Plan’)
Date of change	16-18 December 2025
No. of securities held prior to change	Direct: 35,170 RSU Performance Rights 932,296 Performance Rights 37,041 Ordinary Shares Indirect: 23,816 Ordinary Shares held by Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan(the ‘Plan’)
Class	Ordinary Shares
Number acquired	326,452 Ordinary Shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	35,170 RSU Performance Rights (as a result of the exercise of RSU Performance Rights) 364,103 Performance Rights (291,282 exercised and 72,821 forfeited as they did not meet the vesting conditions) 129,736 Ordinary Shares disposed following the exercise of Performance Rights, sold to cover tax obligations.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration for exercise of Performance Rights and RSU Performance Rights. $401,341.04 received for Ordinary Shares sold to cover tax obligations.
No. of securities held after change	Direct: Nil RSU Performance Rights 568,193 Performance Rights 37,041 Ordinary Shares Indirect: 220,532 Ordinary Shares held by Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan (the ‘Plan’)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights and RSU Performance Rights pursuant to the Plan On market sale of Ordinary Shares.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest
Name of registered holder (if issued securities)
Date of change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3